Project Grant R01CA289548
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$691K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,231,538.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on genetic testing, counseling, and management of cancer in Africa. The award period runs from July 1, 2024 to June 30, 2027. The project involves conducting cancer genetic testing and counseling initiatives in Rwanda, with a focus on building local capacity and integrating...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,456,920 to fund the development and validation of a point-of-care breast cancer diagnostic kit tailored for primary care clinics in Uganda. The project aims to optimize, validate, and deploy a novel diagnostic kit that combines an automated AI-enabled whole breast ultrasound and a smartphone-enabled AI-powered device for cytology and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $368,070 to conduct research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The research aims to investigate factors that negatively impact follow-up appointment attendance and engagement with necessary cervical cancer treatment for women with HIV, in order to develop a tailored intervention to improve...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The funding will be used to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMICs). Specifically, the project aims to:...
The Project Grant award K08CA289935, funded by the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398), supports research to optimize a bundled breast and cervical cancer screening program in Cameroon. The $192,780 award to the University of Alabama at Birmingham aims to 1) establish the reach and effectiveness of the bundled screening program across stationary and mobile clinics, 2) identify implementation outcomes such as acceptability, appropriateness, and cost, and...
This federal Cooperative Agreement award, totaling $706,365.00, was issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award aims to implement the World Health Organization-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project seeks to address barriers to adoption, integration, and sustainability of evidence-based...
The National Cancer Institute (NCI), under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1,729,890 Cooperative Agreement to The Washington University to develop and validate a new medical imaging technology, called SkinScan3D, for improved Kaposi Sarcoma (KS) treatment monitoring in East Africa. The project, titled "PRIME-KS", involves refining the SkinScan3D device, assessing its accuracy and reproducibility compared to standard-of-care methods, and...
This $287,219 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support Dr. O'Neil at Yale University in designing and piloting implementation strategies for introducing screening clinical breast examination (SCBE) at primary health centers in Johannesburg, South Africa. The primary goal is to provide Dr. O'Neil with four years of training and research experience in implementation science and mixed-methods techniques to support his...
This federal Project Grant award, with total funding of $644,804, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393). The grant aims to develop and validate a novel deep learning-based tool for accurately assessing long-term (5-year) breast cancer risk among Black women, a population with persistently higher breast cancer mortality than white women. The award supports three key objectives: 1) developing a deep...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, totaling $1,288,122, aims to identify multi-level factors associated with HPV vaccine uptake in Kenya and Malawi. The key products and services to be delivered include: Primary and secondary data collection on policy, systems, community, and individual-level factors impacting HPV vaccine uptake in Kenya and Malawi. This includes qualitative interviews...